Where Ligand Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Ligand Pharmaceuticals (NASDAQ:LGND) stock. The company has an average price target of $123.25, up by 2.71% from the previous average price target of $120.00. The majority of the ratings are bullish.
September 19, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals has received mostly bullish ratings from analysts, with an increased average price target of $123.25.
The bullish ratings and increased price target indicate a positive outlook for Ligand Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100